Literature DB >> 7913368

Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study.

Y Umekita1, T Takasaki, H Yoshida.   

Abstract

To clarify whether p53 protein expression is involved in multistep carcinogenesis or the progression of mammary ductal carcinoma, we investigated p53 protein expression in 83 invasive ductal carcinomas (IDC), 10 IDC with a predominant intraductal component, 13 non-invasive ductal carcinoma (NIDC), 16 atypical ductal hyperplasia (ADH) and 39 benign epithelial hyperplasia (EH), using immunohistochemistry. Expression of p53 protein was detected in 24 (28.9%) cases of IDC, 5 (50%) cases of IDC with a predominant intraductal component and 1 (7.6%) case of NIDC. No expression was observed in either ADH or EH. In IDC, including cases with a predominant intraductal component, p53 protein expression was associated with a higher histological grade (P < 0.0001) or mitotic index (P < 0.0005). Although overexpression of c-erbB-2 protein has also shown a similar association with these prognostic indicators, expression of p53 protein correlated regardless of the status of c-erbB-2 overexpression. Completely coordinated expression of p53 protein was seen in both intraductal and invasive components. The intraductal component in IDC including cases with a predominant intraductal component which expresses p53 protein had significantly higher histological grade (P < 0.0005) or more comedo-subtypes (P < 0.0001). These results suggested that p53 protein expression occurs at a stage of NIDC with high histological grade or in comedo-subtypes. Its expression is maintained throughout invasion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913368     DOI: 10.1007/bf00191434

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  17 in total

1.  Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

Authors:  E Reihsaus; M Kohler; S Kraiss; M Oren; M Montenarh
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

2.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

3.  Expression of p53 protein in infiltrating and in-situ breast carcinomas.

Authors:  R A Walker; S J Dearing; D P Lane; J M Varley
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

4.  Monoclonal antibodies to human type IV collagen: useful reagents to demonstrate the heterotrimeric nature of the molecule.

Authors:  B F Odermatt; A B Lang; J R Rüttner; K H Winterhalter; B Trüeb
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?

Authors:  D M Barnes; E A Dublin; C J Fisher; D A Levison; R R Millis
Journal:  Hum Pathol       Date:  1993-05       Impact factor: 3.466

7.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

8.  Maintenance of p53 alterations throughout breast cancer progression.

Authors:  A M Davidoff; B J Kerns; J D Iglehart; J R Marks
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

9.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

Authors:  C A Midgley; C J Fisher; J Bártek; B Vojtĕsek; D Lane; D M Barnes
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

10.  p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.

Authors:  H Tsuda; K Iwaya; T Fukutomi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1993-04
View more
  2 in total

1.  Biologic characteristics of premalignant breast disease.

Authors:  Kimberly Cole; Maria Tabernero; Karen S Anderson
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 2.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.